$CORT
Corcept Therapeutics Inc

2024 Q4 Form 10-Q Financial Statement

#000162828024044322 Filed on October 30, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $182.5M
YoY Change 47.69%
Cost Of Revenue $2.867M
YoY Change 74.29%
Gross Profit $179.7M
YoY Change 47.33%
Gross Profit Margin 98.43%
Selling, General & Admin $73.75M
YoY Change 62.93%
% of Gross Profit 41.04%
Research & Development $59.34M
YoY Change 30.36%
% of Gross Profit 33.02%
Depreciation & Amortization $318.0K
YoY Change 218.0%
% of Gross Profit 0.18%
Operating Expenses $133.1M
YoY Change 46.6%
Operating Profit $46.60M
YoY Change 49.46%
Interest Expense $6.345M
YoY Change 22.02%
% of Operating Profit 13.62%
Other Income/Expense, Net $6.345M
YoY Change 21.83%
Pretax Income $52.94M
YoY Change 45.51%
Income Tax $5.700M
% Of Pretax Income 10.77%
Net Earnings $47.21M
YoY Change 50.47%
Net Earnings / Revenue 25.86%
Basic Earnings Per Share $0.45
Diluted Earnings Per Share $0.41
COMMON SHARES
Basic Shares Outstanding 104.8M shares 104.5M shares
Diluted Shares Outstanding 113.7M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $380.3M
YoY Change 7.08%
Cash & Equivalents $137.3M
Short-Term Investments $243.0M
Other Short-Term Assets $4.580M
YoY Change -86.61%
Inventory $8.050M
Prepaid Expenses $5.817M
Receivables $59.72M
Other Receivables $0.00
Total Short-Term Assets $467.0M
YoY Change 8.22%
LONG-TERM ASSETS
Property, Plant & Equipment $2.930M
YoY Change 870.2%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $167.3M
YoY Change 180.72%
Other Assets $6.973M
YoY Change 6.62%
Total Long-Term Assets $317.3M
YoY Change 95.25%
TOTAL ASSETS
Total Short-Term Assets $467.0M
Total Long-Term Assets $317.3M
Total Assets $784.3M
YoY Change 32.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $18.58M
YoY Change 11.21%
Accrued Expenses $79.46M
YoY Change 14.12%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $126.2M
YoY Change 3.56%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $19.21M
YoY Change 82.91%
Total Long-Term Liabilities $19.21M
YoY Change 82.91%
TOTAL LIABILITIES
Total Short-Term Liabilities $126.2M
Total Long-Term Liabilities $19.21M
Total Liabilities $145.4M
YoY Change 9.88%
SHAREHOLDERS EQUITY
Retained Earnings $513.0M
YoY Change 38.21%
Common Stock $806.5M
YoY Change 11.62%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $638.8M
YoY Change
Total Liabilities & Shareholders Equity $784.3M
YoY Change 32.02%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income $47.21M
YoY Change 50.47%
Depreciation, Depletion And Amortization $318.0K
YoY Change 218.0%
Cash From Operating Activities $73.83M
YoY Change 39.3%
INVESTING ACTIVITIES
Capital Expenditures $1.635M
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$42.40M
YoY Change -61.31%
Cash From Investing Activities -$44.04M
YoY Change -59.82%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -21.09M
YoY Change 440.82%
NET CHANGE
Cash From Operating Activities 73.83M
Cash From Investing Activities -44.04M
Cash From Financing Activities -21.09M
Net Change In Cash 8.701M
YoY Change -114.38%
FREE CASH FLOW
Cash From Operating Activities $73.83M
Capital Expenditures $1.635M
Free Cash Flow $72.19M
YoY Change 36.22%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Local Phone Number
LocalPhoneNumber
327-3270
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
CORT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
104775137 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
137289000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
120000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
17396000 usd
CY2024Q3 cort Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
27736000 usd
CY2023Q4 cort Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
21330000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
79464000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
51628000 usd
CY2024Q3 us-gaap Loss Contingency Accrual Carrying Value Current
LossContingencyAccrualCarryingValueCurrent
0 usd
CY2023Q4 us-gaap Loss Contingency Accrual Carrying Value Current
LossContingencyAccrualCarryingValueCurrent
14000000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
432000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
151000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
126216000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
104505000 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
182546000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
123601000 usd
CY2024Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2867000 usd
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1645000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
59336000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
45517000 usd
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
73745000 usd
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
45262000 usd
CY2024Q3 us-gaap Costs And Expenses
CostsAndExpenses
135948000 usd
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
92424000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
46598000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
31177000 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6345000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5208000 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
52943000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
47213000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
31378000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
31172000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
31172000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
109344000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
109344000 usd
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.41
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.28
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
47213000 usd
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-256000 usd
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
31000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
951000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-95000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
536000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-184000 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
48700000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
31099000 usd
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001088856
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
243047000 usd
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
232670000 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
59717000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
41123000 usd
CY2024Q3 us-gaap Loss Contingency Receivable Current
LossContingencyReceivableCurrent
0 usd
CY2023Q4 us-gaap Loss Contingency Receivable Current
LossContingencyReceivableCurrent
14000000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
8050000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
7730000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
18875000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2930000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
195000 usd
CY2024Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
167310000 usd
CY2023Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
57176000 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6973000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6541000 usd
CY2024Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
126799000 usd
CY2023Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
90605000 usd
CY2024Q3 us-gaap Assets
Assets
784257000 usd
CY2023Q4 us-gaap Assets
Assets
621517000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
18584000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
36385000 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5730000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5007000 usd
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
46690000 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.45
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.31
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
102014000 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
113723000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
111099000 shares
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
31378000 usd
dei Document Type
DocumentType
10-Q
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
CORCEPT THERAPEUTICS INC
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0487658
dei Entity Address Address Line1
EntityAddressAddressLine1
101 Redwood Shores Parkway
dei Entity Address City Or Town
EntityAddressCityOrTown
Redwood City
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94065
dei City Area Code
CityAreaCode
650
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
135551000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
27562000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
466978000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
458636000 usd
CY2024Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
7764000 usd
CY2023Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
8244000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5503000 usd
dei Entity File Number
EntityFileNumber
000-50679
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 usd
CY2024Q3 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
12847000 usd
CY2023Q4 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
10307000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
145422000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
114812000 usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
135000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
133000 usd
CY2024Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
682177000 usd
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
635078000 usd
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
806317000 usd
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
738515000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
3927000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2959000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 usd
cort Payments For Repurchase Of Common Stock In Connection With Tender Offer
PaymentsForRepurchaseOfCommonStockInConnectionWithTenderOffer
145428000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
15316000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
8111000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-23785000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-149489000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1738000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
45471000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
135551000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
66329000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
609000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
402526000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
638835000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
506705000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
784257000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
621517000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
493150000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
346970000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7926000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4604000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
176587000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
129646000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
196948000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
137107000 usd
us-gaap Costs And Expenses
CostsAndExpenses
381461000 usd
us-gaap Costs And Expenses
CostsAndExpenses
271357000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
111689000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
75613000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
17844000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
12135000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
129533000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
87748000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
19070000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12963000 usd
us-gaap Net Income Loss
NetIncomeLoss
110463000 usd
us-gaap Net Income Loss
NetIncomeLoss
74785000 usd
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
46690000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.72
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.98
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.66
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
103094000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
103933000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
111571000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
112054000 shares
us-gaap Net Income Loss
NetIncomeLoss
110463000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-139000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-184000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
432000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
586000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
530000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
49000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
111425000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
75420000 usd
us-gaap Profit Loss
ProfitLoss
110463000 usd
us-gaap Profit Loss
ProfitLoss
74785000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
44558000 usd
cort Accretion Expense Income
AccretionExpenseIncome
-8747000 usd
cort Accretion Expense Income
AccretionExpenseIncome
-5933000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
514000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-36333000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
362000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1262000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
18594000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3569000 usd
us-gaap Increase Decrease In Insurance Settlements Receivable
IncreaseDecreaseInInsuranceSettlementsReceivable
-14000000 usd
us-gaap Increase Decrease In Insurance Settlements Receivable
IncreaseDecreaseInInsuranceSettlementsReceivable
0 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-383000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-936000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5579000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
432000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
0 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1616000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4783000 usd
cort Increase Decrease In Accrued Research And Development Expenses
IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
6406000 usd
cort Increase Decrease In Accrued Research And Development Expenses
IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
6732000 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
27531000 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
36695000 usd
cort Increase Decrease In Accrued Settlement Litigation Liabilities
IncreaseDecreaseInAccruedSettlementLitigationLiabilities
-14000000 usd
cort Increase Decrease In Accrued Settlement Litigation Liabilities
IncreaseDecreaseInAccruedSettlementLitigationLiabilities
0 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
2540000 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
1373000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
38000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1215000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
138767000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
121152000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2051000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
139000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
332545000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
372793000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
443738000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
298846000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-113244000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
73808000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
3268000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
15664000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
137289000 usd
cort Shares Repurchased In Net Settlement Of Cashless Option Exercise
SharesRepurchasedInNetSettlementOfCashlessOptionExercise
14184000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
506705000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3485000 usd
CY2024Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
476000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
1283000 usd
CY2024Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-351000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
27762000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
547864000 usd
CY2024Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
1487000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
47213000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
638835000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10966000 usd
CY2023Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
716000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
15879000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
529584000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
828000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-25821000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-8462000 usd
cort Shares Repurchased In Net Settlement Of Cashless Option Exercise
SharesRepurchasedInNetSettlementOfCashlessOptionExercise
22199000 usd
CY2024Q1 cort Treasury Stock Value Acquired Excise Tax Expense Benefit
TreasuryStockValueAcquiredExciseTaxExpenseBenefit
81000 usd
CY2024Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
3478000 usd
CY2024Q2 cort Treasury Stock Value Acquired Excise Tax Expense Benefit
TreasuryStockValueAcquiredExciseTaxExpenseBenefit
16000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13881000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
1314000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
35488000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7574000 usd
CY2024Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
6242000 usd
CY2024Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
3478000 usd
CY2024Q2 cort Treasury Stock Value Acquired Excise Tax Expense Benefit
TreasuryStockValueAcquiredExciseTaxExpenseBenefit
16000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13881000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
1314000 usd
CY2024Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-174000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
35488000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
596243000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10322000 usd
CY2024Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
19704000 usd
CY2024Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
11710000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14286000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
596243000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10322000 usd
CY2024Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
19704000 usd
CY2024Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
11710000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14286000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
698000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
698000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
501842000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6540000 usd
CY2023Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
6359000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4497000 usd
CY2023Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
4823000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
501842000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6540000 usd
CY2023Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
6359000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4497000 usd
CY2023Q2 cort Treasury Stock Value Acquired Excise Tax Expense Benefit
TreasuryStockValueAcquiredExciseTaxExpenseBenefit
-1316000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11374000 usd
CY2023Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
198000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
27528000 usd
CY2023Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
145428000 usd
CY2023Q2 cort Treasury Stock Value Acquired Excise Tax Expense Benefit
TreasuryStockValueAcquiredExciseTaxExpenseBenefit
-1316000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11374000 usd
CY2023Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
198000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
27528000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
421614000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
421614000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
13950000 usd
CY2023Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
17866000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
13950000 usd
CY2023Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
17866000 usd
CY2023Q3 cort Treasury Stock Value Acquired Excise Tax Expense Benefit
TreasuryStockValueAcquiredExciseTaxExpenseBenefit
152000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11660000 usd
CY2023Q3 cort Treasury Stock Value Acquired Excise Tax Expense Benefit
TreasuryStockValueAcquiredExciseTaxExpenseBenefit
152000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11660000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
1070000 usd
CY2023Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-279000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
31378000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
1070000 usd
CY2023Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-279000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
31378000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
461679000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
461679000 usd
cort Number Of Compounds
NumberOfCompounds
1000 compound
cort Number Of Series Of Selective Cortisol Modulators
NumberOfSeriesOfSelectiveCortisolModulators
4 series
cort Number Of Compounds
NumberOfCompounds
1000 compound
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6359000 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1571000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
512989000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
74353000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
74353000 usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
103371000 shares
us-gaap Net Income Loss
NetIncomeLoss
74785000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
35875000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1091000 usd
cort Payments For Repurchase Of Common Stock In Connection With Tender Offer
PaymentsForRepurchaseOfCommonStockInConnectionWithTenderOffer
0 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
111800000 usd
CY2024Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
3554000 usd
CY2024Q1 cort Treasury Stock Value Acquired Excise Tax Expense Benefit
TreasuryStockValueAcquiredExciseTaxExpenseBenefit
81000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12929000 usd
CY2024Q3 cort Inventory Work In Process Current And Noncurrent
InventoryWorkInProcessCurrentAndNoncurrent
7764000 usd
CY2023Q4 cort Inventory Work In Process Current And Noncurrent
InventoryWorkInProcessCurrentAndNoncurrent
8233000 usd
CY2024Q3 cort Inventory Finished Goods Current And Noncurrent
InventoryFinishedGoodsCurrentAndNoncurrent
8050000 usd
CY2023Q4 cort Inventory Finished Goods Current And Noncurrent
InventoryFinishedGoodsCurrentAndNoncurrent
7741000 usd
CY2024Q3 cort Inventory Current Noncurrent
InventoryCurrentNoncurrent
15814000 usd
CY2023Q4 cort Inventory Current Noncurrent
InventoryCurrentNoncurrent
15974000 usd
CY2024Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
7764000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
7730000 usd
CY2024Q3 cort Number Of Manufacturers
NumberOfManufacturers
2 manufacturer
CY2024Q3 cort Inventory Work In Process Current And Noncurrent
InventoryWorkInProcessCurrentAndNoncurrent
7764000 usd
CY2023Q4 cort Inventory Work In Process Current And Noncurrent
InventoryWorkInProcessCurrentAndNoncurrent
8233000 usd
CY2024Q3 cort Inventory Finished Goods Current And Noncurrent
InventoryFinishedGoodsCurrentAndNoncurrent
8050000 usd
CY2023Q4 cort Inventory Finished Goods Current And Noncurrent
InventoryFinishedGoodsCurrentAndNoncurrent
7741000 usd
CY2024Q3 cort Inventory Current Noncurrent
InventoryCurrentNoncurrent
15814000 usd
CY2023Q4 cort Inventory Current Noncurrent
InventoryCurrentNoncurrent
15974000 usd
CY2024Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
7764000 usd
CY2023Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
8244000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
8050000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
7730000 usd
CY2024Q3 cort Number Of Manufacturers
NumberOfManufacturers
2 manufacturer
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5817000 usd
CY2024Q3 cort Deferred Clinical Materials Current
DeferredClinicalMaterialsCurrent
5707000 usd
CY2023Q4 cort Deferred Clinical Materials Current
DeferredClinicalMaterialsCurrent
13496000 usd
CY2024Q3 cort Clinical Deposits Current
ClinicalDepositsCurrent
2771000 usd
CY2023Q4 cort Clinical Deposits Current
ClinicalDepositsCurrent
3865000 usd
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
4580000 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
5882000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
18875000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
27562000 usd
CY2024Q3 cort Accrued Government Rebate Current
AccruedGovernmentRebateCurrent
38799000 usd
CY2023Q4 cort Accrued Government Rebate Current
AccruedGovernmentRebateCurrent
18468000 usd
CY2024Q3 cort Accrued Compensation Current
AccruedCompensationCurrent
27568000 usd
CY2023Q4 cort Accrued Compensation Current
AccruedCompensationCurrent
25457000 usd
CY2024Q3 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
3959000 usd
CY2023Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
1771000 usd
CY2024Q3 cort Accrued Legal Fees Current
AccruedLegalFeesCurrent
1836000 usd
CY2023Q4 cort Accrued Legal Fees Current
AccruedLegalFeesCurrent
542000 usd
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
7302000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5390000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
79464000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
51628000 usd
CY2024Q3 cort Deposits For Clinical Trials
DepositsForClinicalTrials
6000000.0 usd
CY2023Q4 cort Deposits For Clinical Trials
DepositsForClinicalTrials
6400000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss
521146000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss
387016000 usd
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5817000 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4319000 usd
CY2024Q3 cort Deferred Clinical Materials Current
DeferredClinicalMaterialsCurrent
5707000 usd
CY2023Q4 cort Deferred Clinical Materials Current
DeferredClinicalMaterialsCurrent
13496000 usd
CY2024Q3 cort Clinical Deposits Current
ClinicalDepositsCurrent
2771000 usd
CY2023Q4 cort Clinical Deposits Current
ClinicalDepositsCurrent
3865000 usd
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
4580000 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
5882000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
18875000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
27562000 usd
CY2024Q3 cort Accrued Government Rebate Current
AccruedGovernmentRebateCurrent
38799000 usd
CY2023Q4 cort Accrued Government Rebate Current
AccruedGovernmentRebateCurrent
18468000 usd
CY2024Q3 cort Accrued Compensation Current
AccruedCompensationCurrent
27568000 usd
CY2023Q4 cort Accrued Compensation Current
AccruedCompensationCurrent
25457000 usd
CY2024Q3 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
3959000 usd
CY2023Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
1771000 usd
CY2024Q3 cort Accrued Legal Fees Current
AccruedLegalFeesCurrent
1836000 usd
CY2023Q4 cort Accrued Legal Fees Current
AccruedLegalFeesCurrent
542000 usd
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
7302000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5390000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
79464000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
51628000 usd
CY2024Q3 cort Deposits For Clinical Trials
DepositsForClinicalTrials
6000000.0 usd
CY2023Q4 cort Deposits For Clinical Trials
DepositsForClinicalTrials
6400000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss
521146000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss
387016000 usd
CY2024Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
2900000 usd
CY2023Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
1700000 usd
cort Marketable Securities Maximum Maturity Period
MarketableSecuritiesMaximumMaturityPeriod
P26M
cort Marketable Securities Short Term Maximum Maturity Period
MarketableSecuritiesShortTermMaximumMaturityPeriod
P1Y
cort Marketable Securities Weighted Average Maturity Period
MarketableSecuritiesWeightedAverageMaturityPeriod
P10M
CY2024Q2 cort Lessee Operating Lease Rentable Area
LesseeOperatingLeaseRentableArea
50632 sqft
us-gaap Operating Lease Expense
OperatingLeaseExpense
2100000 usd
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
600000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
1800000 usd
CY2024Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
0 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
1774000 usd
CY2024Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
CY2023Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
297000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
5745000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
297000 usd
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P69M
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9M
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.085
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.080
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
0 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1382000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1551000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1598000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1646000 usd
CY2024Q3 cort Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
2555000 usd
CY2024Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
2900000 usd
CY2023Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
1700000 usd
cort Marketable Securities Maximum Maturity Period
MarketableSecuritiesMaximumMaturityPeriod
P26M
cort Marketable Securities Short Term Maximum Maturity Period
MarketableSecuritiesShortTermMaximumMaturityPeriod
P1Y
cort Marketable Securities Weighted Average Maturity Period
MarketableSecuritiesWeightedAverageMaturityPeriod
P10M
CY2024Q3 cort Loss Contingency Accrual Other
LossContingencyAccrualOther
0 usd
CY2024Q3 cort Loss Contingency Accrual Provision Other
LossContingencyAccrualProvisionOther
0 usd
CY2024Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P6Y
CY2024Q2 cort Lessee Operating Lease Rentable Area
LesseeOperatingLeaseRentableArea
50632 sqft
CY2024Q2 cort Operating Lease Liability Obligated Base Rent
OperatingLeaseLiabilityObligatedBaseRent
1500000 usd
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
700000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
2100000 usd
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
600000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
1800000 usd
CY2024Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
0 usd
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
617000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
1358000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
1774000 usd
CY2024Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
CY2023Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
297000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
5745000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
297000 usd
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9M
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.085
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.080
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
0 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1646000 usd
CY2024Q3 cort Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
2555000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
8732000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1941000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
6791000 usd
cort Number Of Stock Option Plans
NumberOfStockOptionPlans
1 plan
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
8000000 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
4100000 shares
CY2024Q3 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
95000 usd
CY2023Q3 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
44000 usd
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
223000 usd
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
170000 usd
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
16197000 usd
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
12919000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
44781000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
36045000 usd
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
46690000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
31172000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
31172000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
109344000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
109344000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
74353000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
74353000 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
102014000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
103094000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
103933000 shares
CY2024Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
10352000 shares
CY2023Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
9085000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
8477000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
8121000 shares
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
8732000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1941000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
6791000 usd
cort Number Of Stock Option Plans
NumberOfStockOptionPlans
1 plan
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
8000000 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
4100000 shares
CY2024Q3 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
95000 usd
CY2023Q3 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
44000 usd
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
223000 usd
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
170000 usd
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
16197000 usd
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
12919000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
44781000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
36045000 usd
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
46690000 usd
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
46690000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
31172000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
31172000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
109344000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
109344000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
74353000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
74353000 usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
103371000 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
102014000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
103094000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
103933000 shares
CY2024Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
10352000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
8477000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
8121000 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
113723000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
111099000 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
113723000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
111099000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
111571000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
112054000 shares
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.45
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.72
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.41
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.28
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.98
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.66
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5700000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
19100000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5000000.0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13000000.0 usd
CY2024Q3 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
1300000 usd
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
111571000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
112054000 shares
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.45
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.72
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.41
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.98
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5700000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5000000.0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13000000.0 usd
CY2024Q3 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
1300000 usd
us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
3400000 usd
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001628280-24-044322-index-headers.html Edgar Link pending
0001628280-24-044322-index.html Edgar Link pending
0001628280-24-044322.txt Edgar Link pending
0001628280-24-044322-xbrl.zip Edgar Link pending
cort-20240930.htm Edgar Link pending
cort-20240930.xsd Edgar Link pending
cort93024ex311.htm Edgar Link pending
cort93024ex312.htm Edgar Link pending
cort93024ex321.htm Edgar Link pending
cort93024ex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
cort-20240930_def.xml Edgar Link unprocessable
cort-20240930_lab.xml Edgar Link unprocessable
cort-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cort-20240930_htm.xml Edgar Link completed
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cort-20240930_cal.xml Edgar Link unprocessable